MedTrace Logo

Effect of Esmolol on Pain Due to Rocuronium

NCT01824758 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 90

Last updated 2019-10-04

No results posted yet for this study

Summary

90 American society of anesthesiology (ASA) physical status I and II patients undergoing general anesthesia for elective surgery will be included in the study. Patients will be randomized into three groups. Group E will receive esmolol (1 mg/kg), Group IL lidocaine (0.5 mg/kg)and Group C placebo(NaCl 0.9%, 5 mL), followed by a 0.05 mg/kg rocuronium. After intravenous induction with propofol, adequate muscle relaxation for intubation will be received by 0.5 mg/kg rocuronium.

Conditions

  • Injection Site Irritation

Interventions

DRUG

Lidocaine

Group L lidocaine (0.5 mg/kg), (rocuronium) (0.05mg/kg).

DRUG

Esmolol

Group E: esmolol (1 mg/kg), (rocuronium) (0.05mg/kg)

DRUG

rocuronium

0.05 mg/kg rocuronium

DRUG

Placebo

Group C: Placebo (NaCl 0.9%, 5 ml), (rocuronium) (0.05mg/kg)

Sponsors & Collaborators

  • Ankara Diskapi Training and Research Hospital

    lead OTHER

Principal Investigators

  • Fakelma 05327079113 · Diskapi Teaching and Research Hospital

Study Design

Allocation
RANDOMIZED
Purpose
SUPPORTIVE_CARE
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2013-03-31
Primary Completion
2013-04-30
Completion
2013-05-31

Countries

  • Turkey (Türkiye)

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01824758 on ClinicalTrials.gov